 Larotrectinib, entrectinib, merestinib, and server other broadly acting tyrosine kinase inhibitors target the "NTRK3" gene.Many of these drugs are in phase 1 or phase 2 clinical trials for the treatment of "ETV6-NTRK3"-related solid tumors and may ultimately prove useful for treating hematologic malignancies associated with this fusion gene.Clinical trials have found that the first generation tyrosine kinase inhibitors sorafenib, sunitinib, midostaurin, lestaurtinib have shown some promise in treating acute myelogenous leukemia associated with the "FLT3-TKI" fusion gene; the second generation tyrosine kinase inhibitors quizartinib and crenolanib which are highly selective in inhibiting the FLT3 protein, have shown significant promise in treating relapsed and refractory acute myelogenous leukemia related to the "FLT3-TKI" fusion gene.